While it is clear that platelets interact with viruses, the ramifications and mechanisms of those interactions are still being defined for each type of viral infection. HIV/AIDS+ represents a potentially unique example of how viremia affects platelets since the increasing efficacy of antiretroviral therapeutics (ART) has made it a chronic disease that increases the risk of cardiovascular disease. In this opinion article, we discuss some of the open questions about how platelets interact with HIV. What happens to a virion once it binds a platelet? What is the nature of virus-induced platelet activation? Are platelets a normal part of the immune response to viremia that has been co-opted to increase the spread of HIV? The answers to these and similar questions will help define how platelet-directed therapeutics might be used in treating HIV/AIDS+ patients.
|Number of pages
|Published - 2022
Bibliographical noteFunding Information:
This work is supported by grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (HL56652, HL138179, and HL150818), and a Department of Veterans Affairs Merit Award to S.W.W.
© 2022 Taylor & Francis Group, LLC.
ASJC Scopus subject areas